Neurofibromatosis type 1 (NF1) is a genetic condition that causes changes in skin pigment and growth of benign tumors along nerves, and it can affect the skin, bones, eyes, and nervous system. You should know that NF1 is a lifelong condition with variable symptoms—some people have mild skin findings while others face learning differences, bone issues, or tumors that need medical attention.
This article What Is NF1 Disease will walk you through how NF1 typically shows up, how clinicians make a diagnosis, and the current approaches to managing symptoms and monitoring risk. Expect clear explanations of common signs like café-au-lait spots and neurofibromas, what triggers further testing, and practical treatment and follow-up strategies clinicians use today.
Symptoms and Diagnostic Criteria
You will often notice skin findings, nerve tumors, and learning or attention issues. Diagnosis combines specific physical signs with family history and, when needed, genetic testing.
Common Physical Manifestations
You may see multiple light-brown café au lait macules at birth or in early childhood. The diagnostic threshold is typically six or more café au lait spots larger than 5 mm in prepubertal children or larger than 15 mm after puberty.
Freckling in the armpits (axillary) or groin (inguinal) is another characteristic sign that often appears by school age.
Cutaneous neurofibromas—soft, benign tumors on or under the skin—emerge later, usually during adolescence and adulthood. Plexiform neurofibromas can be congenital and may grow along nerves, causing pain, disfigurement, or functional problems.
You might also have Lisch nodules (pigmented iris hamartomas) seen on eye exam; they do not affect vision but support diagnosis.
Neurological Signs
You can experience learning disabilities, attention deficit disorder, or developmental delays; about half of people with NF1 have cognitive or behavioral challenges. Early screening for language, motor skills, and academic progress helps guide interventions.
Optic pathway gliomas may develop, often in young children, and can cause vision loss or proptosis; routine ophthalmologic surveillance is recommended. Seizures and headaches occur in a minority of patients and warrant neuroimaging when new or progressive.
Neurological deficits from tumor compression, spinal cord involvement, or bony abnormalities (scoliosis) can produce focal weakness, pain, or sensory changes that require specialty care.
Genetic Testing NF1 Disease Methods
You can confirm NF1 by finding a pathogenic NF1 gene variant through molecular testing of blood or saliva DNA. Single-gene sequencing (including deletion/duplication analysis) detects most variants; targeted tests identify large deletions or complex rearrangements.
If a known familial NF1 mutation exists, targeted testing of relatives provides a rapid diagnosis. In mosaic or segmental cases, standard blood testing may be negative; testing of affected tissue or skin biopsy can increase detection.
Genetic counseling helps you interpret results, understand recurrence risks, and plan family testing or prenatal options.
Current Management Strategies
Management focuses on regular surveillance for tumor growth and complications, targeted medical or surgical treatments when needed, and coordinated support services to help you navigate care and daily life.
Monitoring and Regular Screenings
You need lifelong, scheduled assessments because NF1 features change with age and can affect multiple organs.
Annual skin and neurologic exams are standard; document new or changing lumps, pain, or focal weakness immediately.
For children, monitor growth, developmental milestones, learning difficulties, and vision with ophthalmologic exams at least annually until school age and then as recommended.
MRI is the primary imaging tool for internal plexiform neurofibromas or suspected optic pathway gliomas; frequency depends on symptoms and prior imaging—often every 6–12 months when tumors are growing or symptomatic.
Baseline blood pressure checks, scoliosis screening, and periodic assessment for skeletal abnormalities help detect non-tumor complications early.
Maintain a personalized surveillance plan with your NF clinic or multidisciplinary team and keep copies of imaging and clinic notes for all providers.
Medical Treatments
Your treatment choice depends on tumor type, location, symptoms, and age.
For symptomatic plexiform neurofibromas, MEK inhibitors (e.g., selumetinib) can shrink tumors and reduce pain—monitor for side effects like rash, gastrointestinal symptoms, and cardiac or ocular changes.
Surgery remains the option for resectable, symptomatic tumors, but risks include nerve injury and recurrence; surgeons specializing in NF1 improve outcomes.
Pain management may combine medications, nerve blocks, and physical therapy; use opioids cautiously and under specialist guidance.
Clinical trials investigate targeted therapies and gene approaches; discuss trial eligibility with your NF care team if standard options are limited.
Supportive Resources for Patients
You should build a care team that includes a geneticist or NF specialist, neurologist, surgeon, ophthalmologist, pain specialist, and allied therapists.
Access to an NF clinic or multidisciplinary center improves coordination and surveillance consistency.
Educational support is crucial—request neuropsychological testing and individualized education plans (IEPs) for learning disabilities or attention issues.
Mental health resources, peer support groups, and patient advocacy organizations provide information, financial aid guidance, and community connections.
Keep an up-to-date emergency plan and a medical summary card listing your diagnosis, key medications, allergies, and recent imaging to share with new providers.
